Journal article
Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial
Abstract
BACKGROUND: BE SURE 1-year results demonstrated the superior efficacy of bimekizumab compared with adalimumab with no unexpected safety findings.
OBJECTIVES: To provide efficacy and safety data over 2 years of bimekizumab treatment compared with adalimumab from BE SURE and the BE BRIGHT open-label extension (OLE) in patients with moderate-to-severe plaque psoriasis.
Authors
Thaçi D; Vender R; de Rie MA; Conrad C; Pariser DM; Strober B; Vanvoorden V; Wang M; Madden C; de Cuyper D
Journal
British Journal of Dermatology, Vol. 188, No. 1, pp. 22–31
Publisher
Oxford University Press (OUP)
Publication Date
January 23, 2023
DOI
10.1093/bjd/ljac021
ISSN
0007-0963